CD47 and neoplasm: Given the increasing evidence of the involvement of tumor microenvironment in remodeling cancer cell responsiveness to TKI therapy, we investigated the expression of CD47 and ecto-CRT in PC9 and HCC827 cell lines after the acquisition of gefitinib resistance in vitro.